GlassScriptPhysician profile
Alan M Fein
NPI 1396784609
$36,134.34
in general payments reported to CMS, 2019-2025
42 companies · $2,787 in 2025
The $2,787 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,795 · 2021: $3,491 · 2022: $4,813 · 2023: $2,839 · 2024: $2,516 · 2025: $2,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,830 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,829.79 |
| Education | $312.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $18,569.33 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $3,845.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Nabriva Therapeutics, Plc | $1,783.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,338.42 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,294.12 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $1,134.97 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $1,107.82 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,031.62 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $828.35 | 2021-2025 | Tezspire |
| Harmony Biosciences LLC | $705.93 | 2020-2025 | Wakix |
| Genzyme Corporation | $670.99 | 2020-2025 | |
| Philips North America LLC | $590.79 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Sunovion Pharmaceuticals INC. | $372.61 | 2019-2020 | |
| Genentech USA, INC. | $353.41 | 2019-2025 | Xolair |
| Electromed, INC. | $281.16 | 2019-2025 | Smartvest |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Fein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.